Investor mix
6 investors on record; lead investors include Panlin Capital, Wuhan Institute of Biotechnology, TD Capital.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 4 | 67% |
| Other / undisclosed | 2 | 33% |
Developer of bi-specific antibodies for cancer treatment
6 investors on record; lead investors include Panlin Capital, Wuhan Institute of Biotechnology, TD Capital.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 4 | 67% |
| Other / undisclosed | 2 | 33% |